Leadership Change at DoP: Senior IAS Officer Manoj Joshi Takes Charge as Pharma Secretary

Written By :  Farhat Nasim
Published On 2026-01-03 11:47 GMT   |   Update On 2026-01-03 11:47 GMT
Advertisement

New Delhi: Senior IAS officer Manoj Joshi has taken charge as the new Secretary of the Department of Pharmaceuticals (DoP) under the Ministry of Chemicals and Fertilizers, marking a key leadership change in the central bureaucracy.

Joshi, a 1989-batch IAS officer from the Kerala cadre, assumed his new role on January 2, 2026, succeeding Amit Aggarwal, who has been shifted to the Department of Telecommunications as part of a broader bureaucratic reshuffle approved by the Appointments Committee of the Cabinet in November 2025.

Advertisement

Also Read: Amit Aggarwal Takes Charge As Secretary of Department of Pharma

Prior to this appointment, he was Secretary of the Department of Land Resources under the Ministry of Rural Development and has held key leadership roles in the Ministry of Housing and Urban Affairs and other central ministries during his central deputation. An engineer by training with a B.E. degree and post-graduate qualifications in management and financial management, Joshi brings extensive administrative experience spanning regulatory coordination, urban development, land administration, and policy implementation across central ministries and government departments. He has been entrusted with the pharmaceuticals portfolio as part of a broader secretary-level reshuffle approved by the Appointments Committee of the Cabinet, reports The Secretariat.

The leadership transition comes at a pivotal time for India’s pharmaceutical and medtech sectors, with the government focusing on initiatives such as the Promotion of Research and Innovation in Pharma MedTech Sector (PRIP) to support and scale domestic innovators and address regulatory and compliance challenges faced by smaller manufacturers.

Joshi’s appointment is expected to shape policy and regulatory oversight in the sector, including efforts to bolster drug manufacturing capabilities, strengthen compliance frameworks, and enhance India’s position as a global pharmaceutical hub.

Full View


Tags:    
Article Source : with inputs

Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.

NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.

Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .

Similar News